Lantern Pharma to Showcase AI-Powered Cancer Drug Discovery and Development on RedChip Webinar on August 26.
ByAinvest
Tuesday, Aug 19, 2025 8:11 am ET1min read
LTRN--
Lantern Pharma's CEO, Panna Sharma, will spotlight the company's advancing clinical pipeline, including LP-300, LP-184, and LP-284. These drug candidates are in various stages of development and target significant markets with urgent unmet needs. LP-300, a Phase 2 Harmonic™ trial in never-smokers with NSCLC, addresses a $4B+ global market. LP-184, a Phase 1 therapy for DDR-deficient solid tumors, targets a $10B+ market. LP-284, a first-in-class drug candidate for aggressive lymphomas, has a market potential of $3.75-4B.
Lantern Pharma's RADR® platform analyzes over 200 billion oncology data points and leverages more than 200 advanced ML algorithms to compress early drug development timelines by up to 70% and reduce costs by 80%. The company has secured 11 FDA designations, an expanding ADC program, and collaborations with world-class cancer centers such as Johns Hopkins and MD Anderson, along with a growing patent estate of over 100 issued and pending patents.
The webinar will also feature a live Q&A session with management, allowing participants to ask questions directly. To register for the free webinar, please visit [RedChip Companies Webinar Page] [NUMBER:1].
References:
[1] https://www.newswire.com/news/redchip-to-host-exclusive-investor-webinar-featuring-lantern-pharma-on-august-26
[2] https://www.nasdaq.com/press-release/redchip-host-exclusive-investor-webinar-featuring-lantern-pharma-august-26-2025-08-19
RedChip Companies will host an investor webinar with Lantern Pharma on August 26, 2025. Lantern's CEO, Panna Sharma, will discuss the company's clinical pipeline, including LP-300, LP-184, and LP-284, and highlight its proprietary AI and machine learning platform, RADR®, which aims to compress early drug development timelines and reduce costs. Questions can be pre-submitted to LTRN@redchip.com or online during the live event.
RedChip Companies will host an exclusive investor webinar with Lantern Pharma Inc. (NASDAQ: LTRN) on August 26, 2025, at 4:15 p.m. ET. The webinar will provide insights into Lantern's innovative approach to cancer drug discovery and development through its proprietary AI and machine learning platform, RADR®.Lantern Pharma's CEO, Panna Sharma, will spotlight the company's advancing clinical pipeline, including LP-300, LP-184, and LP-284. These drug candidates are in various stages of development and target significant markets with urgent unmet needs. LP-300, a Phase 2 Harmonic™ trial in never-smokers with NSCLC, addresses a $4B+ global market. LP-184, a Phase 1 therapy for DDR-deficient solid tumors, targets a $10B+ market. LP-284, a first-in-class drug candidate for aggressive lymphomas, has a market potential of $3.75-4B.
Lantern Pharma's RADR® platform analyzes over 200 billion oncology data points and leverages more than 200 advanced ML algorithms to compress early drug development timelines by up to 70% and reduce costs by 80%. The company has secured 11 FDA designations, an expanding ADC program, and collaborations with world-class cancer centers such as Johns Hopkins and MD Anderson, along with a growing patent estate of over 100 issued and pending patents.
The webinar will also feature a live Q&A session with management, allowing participants to ask questions directly. To register for the free webinar, please visit [RedChip Companies Webinar Page] [NUMBER:1].
References:
[1] https://www.newswire.com/news/redchip-to-host-exclusive-investor-webinar-featuring-lantern-pharma-on-august-26
[2] https://www.nasdaq.com/press-release/redchip-host-exclusive-investor-webinar-featuring-lantern-pharma-august-26-2025-08-19
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet